RESCAP platform : Disease modifying therapeutics in Parkinson Disease, Diabetes and Rheumatoid Arthritis. Empowering Innate Immunity
AMRIF focuses on developing safe and well tolerated treatments for chronic inflammatory diseases.
COVID19 RESCAP intervention. Participating hospitals and sister company Alloksys receive fast track approval
RESCAP intervention in critically ill SARS-COV2 infected patients admitted to ICU has been approved through the Dutch...
RESCAP intervention in Rheumatoid Arthritis: a first step, establishment Proof of Principle in representative animal model
Clinical phase 2 trial in RA patients with RESCAP at VUmc Amsterdam (Amsterdam UMC) under supervision of Dr C van der...
AMRIF collaborates with Holland Food Ventures and TDI in development of sensors for early detection and monitoring of...
AMRIF is a spin-off company of Alloksys Life Sciences. Leveraging on the RESCAP® platform, we develop therapies for chronic diseases with an underlying problem of systemic inflammation. Our near term focus is on unmet medical disease applications in Neuro Degenerative Diseases (PD, ALZ), arthritis and diabetic complications.
AMRIF’s human recombinant therapeutic protein hRESCAP has completed a Ph l clinical study. Native bRESCAP is applied in several clinical studies.
How we work together with clinicians, hospitals and other institutions to help patients with unmet medical need diseases.
In this video:
- What is RESCAP?
- Our research on protecting barriers and anti-inflammatory action
- More information on our partnerships to transfer our products to the market
We are very proud to work with:
Participating Clinicians and clinical centers and Aix Scientifics as global CRO in ongoing and planned clinical trials as well as investors and Dutch RVO innovation credit facility.